URB602 10 mg | 99.64%
TargetMol
URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.
More Information Supplier PageURB602
Search Results
URB602 100 mg | 99.64%
TargetMol
URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.
More Information Supplier PageKS176 5 mg | 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information Supplier PageKS176
KS176 50 mg | 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information Supplier PageKS176
NVP-ACC789 5 mg | 99.19%
TargetMol
ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
More Information Supplier PageNVP-ACC789
NVP-ACC789 50 mg | 99.19%
TargetMol
ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
More Information Supplier PageNVP-ACC789
NVP-ACC789 25 mg | 99.19%
TargetMol
ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
More Information Supplier PageNVP-ACC789
NVP-ACC789 10 mg | 99.19%
TargetMol
ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
More Information Supplier PageNVP-ACC789
S107 5 mg | 99.63%
TargetMol
S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
More Information Supplier PageS107
S107 50 mg | 99.63%
TargetMol
S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
More Information Supplier PageS107